The effects of bazedoxifene on bone structural strength evaluated by hip structure analysis

Area of Science:

• Osteoporosis Research
• Bone Biology
• Pharmacology

Background:

• Postmenopausal osteoporosis is a significant health concern, increasing fracture risk.
• Selective estrogen receptor modulators (SERMs) like Bazedoxifene (BZA) are used for prevention and treatment.
• Hip structure analysis (HSA) provides detailed bone geometry insights from BMD scans.

Purpose of the Study:

• To evaluate BZA's effect on hip structural geometry in postmenopausal women using HSA.
• To assess changes in bone strength-related parameters over 2 years.
• To analyze BZA's efficacy in women at increased fracture risk.

Main Methods:

• Exploratory analysis of a phase 3 osteoporosis study cohort (n=521 or n=475).
• Hip dual-energy X-ray absorptiometry (DXA) scans analyzed with HSA at baseline and 24 months.
• Analysis of covariance used to compare percent changes in BMD and geometric parameters (SM, CSA, OD, BR) between BZA and placebo groups.

Main Results:

• BZA treatment significantly increased bone mineral density (BMD) and improved hip structural geometry across all analyzed regions.
• Specifically, BZA increased section modulus (SM), cross-sectional area (CSA), and outer diameter (OD) in the narrow neck region (P < 0.05).
• In the intertrochanter region, BZA increased CSA and BMD and decreased buckling ratio (BR) (P < 0.05), indicating enhanced bone strength.

Conclusions:

• Bazedoxifene (BZA) treatment is associated with geometry-related improvements in bone strength, enhancing resistance to bending and compressive forces.
• These positive effects were observed at critical fracture sites like the femoral neck and intertrochanter regions.
• The findings support BZA's role in reducing nonvertebral fractures in high-risk postmenopausal women with osteoporosis.